<table>
<thead>
<tr>
<th>Ordinal Position</th>
<th>Field Name (.TXT) Header Row (.CSV)</th>
<th>Size</th>
<th>Position</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Record ID</td>
<td>4</td>
<td>1 - 4</td>
<td>Constant of “01@@”</td>
</tr>
<tr>
<td>2</td>
<td>Labeler Code</td>
<td>5</td>
<td>5 - 9</td>
<td>NDC 1</td>
</tr>
<tr>
<td>3</td>
<td>Product Code</td>
<td>4</td>
<td>10 - 13</td>
<td>NDC 2</td>
</tr>
<tr>
<td>4</td>
<td>Package Size</td>
<td>2</td>
<td>14 - 15</td>
<td>NDC 3</td>
</tr>
<tr>
<td>5</td>
<td>Period Covered</td>
<td>5</td>
<td>16 - 20</td>
<td>QYYYY</td>
</tr>
<tr>
<td>6</td>
<td>FDA Product Name</td>
<td>10</td>
<td>21 - 30</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>7</td>
<td>Drug Category</td>
<td>1</td>
<td>31 - 31</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>8</td>
<td>Therapeutic Equivalence Code</td>
<td>2</td>
<td>32 - 33</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>9</td>
<td>Unit Type</td>
<td>3</td>
<td>34 - 36</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>10</td>
<td>Units Per Package Size</td>
<td>11</td>
<td>37 - 47</td>
<td>99999999.999</td>
</tr>
<tr>
<td>11</td>
<td>Unit Rebate Amount</td>
<td>15</td>
<td>48 - 62</td>
<td>99999999.99999</td>
</tr>
<tr>
<td>12</td>
<td>URA Type</td>
<td>1</td>
<td>63 - 63</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>13</td>
<td>FDA Approval Date</td>
<td>8</td>
<td>64 - 71</td>
<td>MMDDYYYY</td>
</tr>
<tr>
<td>14</td>
<td>Market Date</td>
<td>8</td>
<td>72 - 79</td>
<td>MMDDYYYY</td>
</tr>
<tr>
<td>15</td>
<td>Termination Date</td>
<td>8</td>
<td>80 - 87</td>
<td>MMDDYYYY</td>
</tr>
<tr>
<td>16</td>
<td>Date Termination Date Certified</td>
<td>8</td>
<td>88 - 95</td>
<td>MMDDYYYY</td>
</tr>
<tr>
<td>17</td>
<td>Drug Type</td>
<td>1</td>
<td>96 - 96</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>18</td>
<td>Clotting Factor Indicator</td>
<td>1</td>
<td>97 - 97</td>
<td>Y or N</td>
</tr>
<tr>
<td>19</td>
<td>Exclusively Pediatric Indicator</td>
<td>1</td>
<td>98 - 98</td>
<td>Y or N</td>
</tr>
<tr>
<td>20</td>
<td>Covered Outpatient Drug Status</td>
<td>2</td>
<td>99 - 100</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>21</td>
<td>FDA Application Number/OTC Monograph Number</td>
<td>7</td>
<td>101 - 107</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>22</td>
<td>Reactivation Date</td>
<td>8</td>
<td>108 - 115</td>
<td>MMDDYYYY</td>
</tr>
<tr>
<td>23</td>
<td>Line Extension Drug Indicator</td>
<td>1</td>
<td>116 - 116</td>
<td>See Data Definitions</td>
</tr>
<tr>
<td>24</td>
<td>Record Type Indicator</td>
<td>1</td>
<td>117 - 117</td>
<td>See Data Definitions</td>
</tr>
</tbody>
</table>

Logical Record Length = 117
Record ID: Constant value of “01@@.”

Labeler Code: First segment of the National Drug Code (NDC) that identifies the labeler.

Product Code: Second segment of the NDC.

Package Size: Third segment of the NDC.

Period Covered: The calendar quarter and year covered by the data submission.

Valid Values for Q:

1 = January 1 - March 31  
2 = April 1 - June 30  
3 = July 1 - September 30  
4 = October 1 - December 31

Valid Values for YYYY: Four-digit calendar year.

FDA Product Name: The first 10 characters of the drug name as it appears on FDA SPL listing.

Drug Category: Indicates whether the drug has been reported as single source, innovator multiple source or non-innovator multiple source.

Valid Values:

S = Single source  
I = Innovator multiple source  
N = Non-innovator multiple source

Therapeutic Equivalence Code (TEC): FDA-assigned Therapeutic Equivalence Codes as found in the FDA’s Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.

Valid Values:

AA = Products in Conventional Dosage Forms not Presenting Bioequivalence Problems
AB = Products Meeting Necessary Bioequivalence Requirements assigned an FDA TEC of AB, or AB1 through AB9
AN = Solutions and Powders for Aerosolization
AO = Injectable Oil Solutions
AP = Injectable Aqueous Solutions and, in Certain Instances, Intravenous Non-Aqueous
AT = Topical Products
BC = Extended-Release Dosage Forms (Capsules, Injectables, and Tablets)
BD = Active Ingredients and Dosage Form with Documented Bioequivalence Problems
BE = Delayed-Release Oral Dosage Forms
BN = Products in Aerosol-Nebulizer Drug Delivery Systems
BP = Active Ingredients and Dosage Forms with Potential Bioequivalence Problems
BR = Suppositories or Enemas that Deliver Drugs for Systemic Absorption
BS = Products Having Drug Standard Deficiencies
BT = Topical Products with Bioequivalence Issues
BX = Drug Products for Which the Data are Insufficient to Determine Therapeutic Equivalence
NR = Not Rated

**Unit Type:** Basic measurement that represents the smallest unit by which the drug is normally dispensed.

*Valid Values:*

AHF = Injectable Anti-Hemophilic Factor
CAP = Capsule
EA = EACH (for drugs not identifiable by any other unit type)
GM = Gram
ML = Milliliter
SUP = Suppository
TAB = Tablet
TDP = Transdermal patch
MCI = Millicurie
UCI = Microcurie

**Units Per Package Size:** The total number of units in the smallest dispensable amount for the 11-digit NDC.

**Unit Rebate Amount:** The CMS-calculated amount (per reported unit type) to be claimed as a rebate by the state.

**URA Type:** The methodology that CMS used to calculate the URA. For any drug that is not a Line Extension, the URA Type will be the Standard methodology, and for Line Extension drugs, the URA Type will be the greater of the Standard or Alternative methodology. NOTE: If a zero URA appears on the quarterly file (i.e., along with a “1” rebate indicator), the URA Type field will be blank.

*Valid Values:*

S = Standard
A = Alternative

**FDA Approval Date:** NDA (including Authorized Generic), ANDA or BLA approval date. For covered outpatient drugs for which the FDA does not require approval, the FDA Approval Date will be 09/30/1990, or, if the drug was first marketed after 09/30/1990, the actual date the drug was first marketed.

**Market Date:** For S, I, and N drugs marketed under an FDA-approved application (e.g. ANDA, BLA, NDA, NDA Authorized Generic), the earliest date the drug was first marketed under the
application number by any labeler. For drugs marketed without an FDA-approved application (e.g. OTC monograph, unapproved drug), the earliest date the drug was first marketed by any labeler. Reported Market Dates that fall earlier than 9/30/1990 (i.e., the start of the Medicaid Drug Rebate Program) are automatically changed to 9/30/1990, since dates earlier than the start of the Medicaid Drug Rebate Program have no bearing on the program.

**Termination Date:** The date the drug was withdrawn from the market or the drug’s last lot expiration date.

**Date Termination Date Certified:** The date on which the reported Termination Date was certified by the labeler in MDP.

**Drug Type:** Identifies the drug as prescription (Rx) or over-the-counter (OTC).

- **Valid Values:**
  - 1 = Rx
  - 2 = OTC

**Clotting Factor Indicator:** In accordance with section 1927(c)(1)(B)(iii) of the Social Security Act, an indicator which identifies a Single Source or Innovator Multiple Source drug as a clotting factor for which a separate furnishing payment is made under section 1842(o)(5) of the Act.

- **Valid Values:**
  - Y = Yes
  - N = No

**Pediatric Indicator:** In accordance with section 1927(c)(1)(B)(iii) of the Social Security Act, an indicator which identifies a Single Source or Innovator Multiple Source drug approved by the FDA exclusively for pediatric indications for patients in the FDA-defined pediatric age group (i.e., birth to 16 years).

- **Valid Values:**
  - Y = Yes
  - N = No

**Covered Outpatient Drug Status:** A category that identifies how a product meets the statutory definition of a covered outpatient drug in accordance with sections 1927(k)(2) to 1927(k)(4) of the Social Security Act.

- **Valid Values:**
  - 01 = Abbreviated New Drug Application (ANDA)
  - 02 = Biological License Application (BLA)
  - 03 = New Drug Application (NDA)
  - 04 = NDA Authorized Generic
  - 05 = DESI 5* – LTE/IRS drug for all indications
  - 06 = DESI 6* – LTE/IRS drug withdrawn from market
07 = Prescription Pre-Natal Vitamin or Fluoride
08 = Prescription Dietary Supplement/Vitamin/Mineral (Other than Prescription Pre-Natal Vitamin or Fluoride)
09 = OTC Monograph Tentative
10 = OTC Monograph Final
11 = Unapproved Drug – Drug Shortage
12 = Unapproved Drug – Per 1927(k)(2)(A)(ii)
13 = Unapproved Drug – Per 1927(k)(2)(A)(iii)

*NDCs with a COD Status of DESI 5/6 are not eligible for coverage or rebates under the Medicaid Drug Rebate Program.

**FDA Application Number/OTC Monograph Number:** For drugs with a COD status of ANDA, BLA, NDA, or NDA Authorized Generic, this is the application number (assigned by the FDA for approval to market a drug or biological in the United States) under which the NDC is currently marketed.

For drugs with a COD status of OTC Monograph Tentative or Final, this is the FDA’s regulatory citation for the OTC. For drugs with a COD Status of OTC Monograph Final, the first four characters are a constant of “PART”; the last three characters are the numeric values for the appropriate regulatory citation for the product (e.g., “225”). For drugs with a COD Status of OTC Monograph Tentative, the first four characters are a constant of “PART”; the last three characters are the numeric values for the appropriate regulatory citation for the product, or 3 zeroes if a Monograph Number is not available.

For drugs with a COD Status other than ANDA, BLA, NDA, NDA Authorized Generic, OTC Monograph Final, or OTC Monograph Tentative, the FDA Application No./OTC Monograph No. field is zero- filled.

**Reactivation Date:** The date on which a terminated product is re-introduced to the market.

**Line Extension Drug Indicator:** Identifies whether a product is a line extension drug as defined in Section 1927(c)(2)(C) of the Social Security Act, including whether the drug is excluded from the statutory definition of a line extension on the basis of being an abuse-deterrent formulation (ADF). If a labeler is seeking an ADF exclusion, a value of “R” will appear in this field. NOTE: If a Line Extension Drug Indicator has not been reported for an NDC, this field will be blank.

**Valid Values:**

Y = Yes
N = No (i.e., neither LE nor ADF)
R = Request for ADF Exclusion
E = Excluded (Due to ADF)

**Record Type Indicator:** Provides information regarding each individual line of data included on a quarterly rebate file.

**Valid Values:**

0 Indicator: Initial, valid URA for an NDC and a particular quarter/year

1 Indicator: Zero URA (due to missing quarterly pricing, 400/400 edit, systems Edits, etc.)
2 Indicator: Value of previously calculated URA

3 Indicator: Value of replacement URA (always appears along with a corresponding 2 Indicator record)

4 Indicator: Value of each initial Termination Date and value of each initial Reactivation Date in a Termination/Reactivation Date set. (Each NDC can have more than one set of Termination/Reactivation Dates.)

5 Indicator: Value of previously reported Termination Date and/or Reactivation Date period

6 Indicator: Value of replacement Termination Date and/or Reactivation Date period (always appears along with a corresponding 5 Indicator record)

7 Indicator: URA for this quarter/year is no longer valid due to a product change by the labeler (e.g., Term. Date change, Market Date change, etc.)

8 Indicator: URA for this quarter/year was previously invalid, but is now valid again due to another product data change by the labeler (e.g., Term. Date change, Market Date change, etc.)